Ocular Therapeutix (OCUL) Income from Continuing Operations (2013 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly Income from Continuing Operations of 90067000.0 in Q1 2026, down 38.04% quarter-over-quarter from 65249000.0 in Q4 2025, and down 42.79% on a YoY basis from 157441898.54 in Q1 2025.
Ocular Therapeutix (OCUL) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 90067000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 42.79% year-over-year to 90067000.0; the TTM figure through Mar 2026 stood at 290489000.0 (down 47.9% YoY), while the FY2025 annual figure was 263497000.0, down 59.62% from the prior year.
- Income from Continuing Operations was 90067000.0 for Q1 2026 at Ocular Therapeutix, down from 65249000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19498000.0 in Q1 2022 to a low of 90067000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 40779705.88 across 5 years, with a median of 31746000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations grew 10.95% in 2022, then plunged 115.51% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 20785000.0 in 2022, then fell by 9.42% to 22742000.0 in 2023, then slumped by 115.51% to 49011000.0 in 2024, then plunged by 33.13% to 65249000.0 in 2025, then tumbled by 38.04% to 90067000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 90067000.0 (Q1 2026), 65249000.0 (Q4 2025), and 67971000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | -90.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.07 Mn |
| Dec 31, 2025 | -65.25 Mn |
| Sep 30, 2025 | -67.97 Mn |
| Jun 30, 2025 | -67.20 Mn |
| Mar 31, 2025 | -63.08 Mn |
| Dec 31, 2024 | -49.01 Mn |
| Sep 30, 2024 | -43.57 Mn |
| Jun 30, 2024 | -40.75 Mn |
| Mar 31, 2024 | -31.75 Mn |
| Dec 31, 2023 | -22.74 Mn |
| Sep 30, 2023 | -21.43 Mn |
| Jun 30, 2023 | -21.81 Mn |
| Mar 31, 2023 | -23.75 Mn |
| Dec 31, 2022 | -20.79 Mn |
| Sep 30, 2022 | -23.06 Mn |
| Jun 30, 2022 | -21.54 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Sep 30, 2021 | -21.18 Mn |
| Jun 30, 2021 | -21.88 Mn |